OTHER INFORMATION
−Removed: During the nine months ended September 30, 2024 , none of our directors or “officers” (as defined in Rule 16a - 1 (f) under the Securities Exchange Act of 1934, as amended) adopted or terminated a “Rule 10b5 - 1 trading arrangement” or “non-Rule 10b5 - 1 trading arrangement,” as each term is defined in Item 408 of Securities and Exchange Commission Regulation S-K.
−Removed: Form of Series A Common Stock Purchase Warrant (Incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed September 16, 2024)
−Removed: Form of Series B Common Stock Purchase Warrant (Incorporated by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed September 16, 2024)
−Removed: Form of Warrant Exercise Agreement, dated September 12, 2024, by and between the Company and the Investor (Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed September 16, 2024)
+Added: During the three months ended March 31, 2025 , none of our directors or “officers” (as defined in Rule 16a - 1 (f) under the Securities Exchange Act of 1934, as amended) adopted or terminated a “Rule 10b5 - 1 trading arrangement” or “non-Rule 10b5 - 1 trading arrangement,” as each term is defined in Item 408 of Securities and Exchange Commission Regulation S-K.
Certificate of CEO of Registrant required under Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended
11 unchanged sentences
BIO-Key International, Inc.
−Removed: November 14, 2024
/s/ Michael W.
1 unchanged sentence
(Principal Executive Officer)
−Removed: November 14, 2024
/s/ Cecilia C.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.